FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes. - Wikidata - wikimedia - TriplyDB

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

http://www.wikidata.org/entity/Q34350591

about

A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

P2860

Q35483823-6E3F96B3-C0B3-44D9-8090-375673B56E02 Q39360428-6E075119-4D1E-473E-BCFA-5A0B8809E7EC Q42559107-5A2BC107-9A24-4B89-BEB1-58F52D120F1C

P2860

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

http://www.wikidata.org/entity/Q34350591

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@ast

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@en

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@nl

type

label

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@ast

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@en

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@nl

prefLabel

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@ast

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@en

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@nl

P1433

Q34350591-622EDBEC-1737-4259-A4ED-76E89129345A

P1476

Q34350591-1D09CD05-DCB5-4F5E-B418-368180CE2664

P2093

Q34350591-0112B325-6ACC-4074-A442-2B8625FD20EE

Q34350591-17C495D0-42D0-42FA-94DF-41D0E5820302

Q34350591-26A514ED-1B69-41D2-A379-93A33C9CCBFB

Q34350591-4950E751-B83C-4EF7-BD24-CA812AD25649

Q34350591-5005E4A0-31C9-484D-BA13-CD4B4E04D303

Q34350591-5080784A-56B8-451E-8046-9765D57FA518

Q34350591-6CFEF2EC-673C-4BFB-BB81-5E708194476D

Q34350591-DC07F5F6-E59F-4676-ACFA-0DD94971EC9D

Q34350591-E0AE2265-682B-4140-BB00-7D9FE40B822F

P2860

Q34350591-067385D6-5AB5-4485-BCE9-4C470834BDDE

Q34350591-06EFACB5-9C3E-4DEF-B72C-6A18140D7E25

Q34350591-1456316B-EF26-4C3B-9DDD-EAC0BE0F38BB

Q34350591-17925091-73C1-4CDA-A1C7-79507B015EEC

Q34350591-28A6F1EC-5584-40B7-8F84-F17C0A4E91A4

Q34350591-2B9E03F8-4E82-4283-93AF-6056F95A2590

Q34350591-32B3A273-9EC0-4C62-8DDB-B2ECAE5C315E

Q34350591-35C5AB3C-172B-4902-A105-238368ABE84A

Q34350591-36B9AC99-C8E1-48EB-B15D-9108B44F8FE7

Q34350591-3E9CF613-D792-4AEE-994C-EF70FA40C5EC

P2888

Q34350591-216501CA-F33E-4816-8742-7355A7AD102C

P304

Q34350591-3244A824-4A57-4FEE-9D38-12B6CB874068

P31

Q34350591-2E21D675-C717-4C36-BB3E-C61BA6A91DC2

P356

Q34350591-C81522D2-862D-406F-938A-DD58D39E4F4D

P433

Q34350591-5BAF75CE-7697-4086-8EE2-0160C36DCF7E

P478

Q34350591-F480EE46-8184-4E1A-8391-D93C7F963415

P577

Q34350591-A4881AE5-7494-4904-AE56-5451BCAB0958

P5875

Q34350591-66C66785-9388-460C-9B9C-D4DEDAE83D22

P6179

Q34350591-44ED6B0C-31E2-42FC-8F59-10D475FFA1BC

P698

Q34350591-9C9E415E-C1C2-4447-818D-C83938A7C1C0

P921

Q34350591-8389656D-6D3B-4781-86DA-D55E18BA1A75

P932

Q34350591-BAFF8AE7-432F-4381-89E5-929517096D64

P356

P1433

Blood Cancer Journal

P1476

FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.

@en

P2093

B Brackertz

http://www.w3.org/2001/XMLSchema#string

B Kast

http://www.w3.org/2001/XMLSchema#string

C Peschel

http://www.w3.org/2001/XMLSchema#string

D H Busch

http://www.w3.org/2001/XMLSchema#string

H Bernhard

http://www.w3.org/2001/XMLSchema#string

H Conrad

http://www.w3.org/2001/XMLSchema#string

H Krönig

http://www.w3.org/2001/XMLSchema#string

J Adamski

http://www.w3.org/2001/XMLSchema#string

J Daniel

http://www.w3.org/2001/XMLSchema#string

P2860

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.

Immunotherapy of hematologic malignancy.

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

P2888

P304

e11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2011.12

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230565399

http://www.w3.org/2001/XMLSchema#string

P6179

1017458277

http://www.w3.org/2001/XMLSchema#string

P698

22829124

http://www.w3.org/2001/XMLSchema#string

P921

P932

3255276

http://www.w3.org/2001/XMLSchema#string